The effect of internal limiting membrane peeling on chronic recalcitrant pseudophakic cystoid macular edema: a report of two cases.

Department of Ophthalmology, Tulane University Health Sciences Center, New Orleans, Louisiana 70112-2699, USA.
American Journal of Ophthalmology (Impact Factor: 4.02). 05/2002; 133(4):571-2. DOI: 10.1016/S0002-9394(01)01402-7
Source: PubMed

ABSTRACT To describe the effect of internal limiting membrane peeling in chronic recalcitrant pseudophakic cystoid macular edema.
Two interventional case reports.
Two consecutive patients with chronic pseudophakic cystoid macular edema of 11-22 months duration, after uncomplicated cataract surgery, unresponsive to previous treatment, were enrolled. The surgical technique consisted of pars plana vitrectomy and internal limiting membrane peeling. Main outcome measures included best-corrected visual acuity, biomicroscopic appearance, and perifoveal leakage on fluorescein angiography. Optical coherence tomography scans were performed postoperatively.
Pars plana vitrectomy with internal limiting membrane peeling resulted in anatomical, angiographic, and functional improvement in both patients, for total follow-up periods of 8 and 11 months, respectively.
To our knowledge, this is the first report of chronic pseudophakic cystoid macular edema that favorably responded to pars plana vitrectomy with internal limiting membrane peeling, as concluded after a MEDLINE search.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Pseudophakic cystoid macular edema (PCME) is a common complication following cataract surgery.38; 130 Acute PCME may resolve spontaneously, but some patients will develop chronic macular edema that affects vision and is difficult to treat. This disease was described more than 50 years ago, and there are multiple options for clinical management. We discuss mechanisms, clinical efficacy, and adverse effects of these treatment modalities. Topical non-steroidal anti-inflammatory agents and corticosteroids are widely used and, when combined, may have a synergistic effect. Intravitreal corticosteroids and anti-vascular endothelial growth factor (anti-VEGF) agents have shown promise when topical medications either fail or have had limited effects. Randomized clinical studies evaluating anti-VEGF agents are needed to fully evaluate benefits and risks. When PCME is either refractory to medical therapy or is associated with significant vitreous involvement, pars plana vitrectomy has been shown to improve outcomes though it is associated with additional risk(s).
    Survey of Ophthalmology 09/2014; 60(2). DOI:10.1016/j.survophthal.2014.08.005 · 3.51 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: .Purpose: To evaluate the effect of intravitreal triamcinolone acetonide for chronic pseudophakic cystoid macular oedema (CME) resistant to medical treatment.Methods: Six eyes of six patients with chronic pseudophakic CME, aged 58–74 years (average 66 years), made up the study population. All eyes had persistent CME despite having received medical treatment for at least 3 months. Intravitreal injection of 4 mg (0.1 ml) triamcinolone acetonide was offered to treat macular oedema. The visual and anatomic responses were observed as well as potential complications related to the injection procedure and corticosteroid medication.Results: The follow-up period was between 6 and 10 months (mean 8.5 months). Baseline central macular thickness averaged 504 µm. At 1 month, a reduction in the mean central macular thickness of 52% from 504 µm to 264 µm was obtained. At 3 and 6 months, the mean central macular thicknesses were 240 µm and 232 µm, respectively. Five of the six eyes maintained a visual gain of 15 or more letters from baseline at 6 months. During follow-up no patient had intraocular pressure (IOP) exceeding 21 mmHg. No injection-related complications were encountered.Conclusions: Intravitreal triamcinolone acetonide is a promising therapeutic method for chronic pseudophakic CME resistant to medical treatment. Further study with a longer follow-up period and larger series is warranted to assess the treatment's longterm efficacy and safety and the need for retreatment.
    Acta Ophthalmologica Scandinavica 12/2003; 81(6):648-652. DOI:10.1046/j.1395-3907.2003.0146.x · 1.85 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Objective or Purpose: Macular edema (ME) is secondary to various disease processes. It is most commonly seen following venous occlusive disease, diabetic retinopathy, posterior segment inflammatory disease, and vitreomacular traction syndromes. Treatment varies, depending upon the underlying etiology, and has led to varying degrees of success. Advances in vitreoretinal surgical techniques over the years have expanded the list of indications for vitreoretinal surgical treatment. The purpose of this review is to outline the current use of vitreoretinal surgery and highlight the ever-growing indications for surgery in macular edema. Design: This is a comprehensive review, using Medline, of all literature published on vitreoretinal surgery for macular edema secondary to various conditions. Results: Over 450 abstracts were reviewed, and the articles pertinent to our discussion were selected. The search words were "macular edema" and "pars plana vitrectomy" or "surgery." Conclusions: The pathology of the vitreous body is associated with ME in several different conditions, and vitreoretinal surgical techniques can be effective in the management of ME in the majority of them. The ever-expanding new surgical techniques, as well as the new pharmacologic agents used during surgery, show great promise for the future.
    Seminars in ophthalmology 01/2014; DOI:10.3109/08820538.2013.796394 · 1.20 Impact Factor